Trump GLP-1 Deal Could Decrease Telehealth Compounding, But Providers Keep Options Open

By Christian Robles / November 26, 2025 at 2:40 PM

The Trump administration’s deal to lower the cost of Lilly and Novo Nordisk GLP-1s for some patients could sway telehealth companies away from prescribing compounded versions of the blockbuster drugs toward brand-name versions, experts told Inside Health Policy.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.